MGF (Mechano Growth Factor): Real Biology, Contested Peptide

At a Glance

MGF is two different things, and conflating them is the root of most of the confusion. The first is a real piece of muscle biology: when muscle is loaded or damaged, the IGF-1 gene is spliced differently, producing a transcript whose E-domain differs from the liver form. That transcript rises before the IGF-1Ea form and tracks satellite cell activation. This is well documented and genuinely interesting for understanding why loading builds muscle and why that process fails with age.

The second is a 24-amino-acid synthetic peptide sold as MGF, whose claimed effects were tested by two pharmaceutical companies and did not reproduce. That negative result deserves more weight than it usually gets, because it was a deliberate reproduction attempt by groups with a commercial incentive to find a positive.

The honest verdict: the biology is real, the peptide is unproven, there are no human trials, and a half-life of a few minutes makes most of the practical rationale for injecting it difficult to defend. Anyone wanting the MGF signal in their muscle already has the reliable method available, which is loading the muscle.

How it works

The splice variant. Total RNA from rabbit muscle undergoing rapid stretch-induced hypertrophy showed two strongly expressed IGF-1 transcripts. The additional isoform, IGF-1Eb, differed from the liver IGF-1Ea form by a 52-base-pair insert in the E-domain, which shifts the reading frame and produces a distinct C-terminal peptide (Yang 1996). The human equivalent is IGF-1Ec, with a 49-base-pair insert.

The expression pattern in people. Eight young men aged 25 to 36 and seven elderly men aged 70 to 82 performed ten sets of six single-leg knee extensions at 80% of one-repetition maximum, with biopsies 2.5 hours later. Resting MGF levels were about 100-fold lower than IGF-1Ea. High-resistance exercise significantly increased MGF mRNA in the young group but not in the elderly, while IGF-1Ea did not change in either (Hameed 2003). That age difference is the single most clinically suggestive finding in this field.

The proposed peptide mechanism, and the dispute. Work from Goldspink’s group reported that the distinct E-domain of MGF inhibits terminal differentiation while increasing myoblast proliferation, and that blocking the IGF-1 receptor with an antibody did not abolish the effect, implying a different receptor (Yang 2002). A later study found that the 24-amino-acid MGF E peptide significantly extended the proliferative lifespan of primary human muscle progenitor cells from neonatal and young adult donors, but not from old adults (Kandalla 2011).

Then came the reproduction attempt. Researchers at two pharmaceutical companies tried to repeat the myoblast findings. MGF peptide at up to 500 ng/mL failed to increase proliferation of C2C12 cells or primary human skeletal muscle myoblasts, and failed to inhibit differentiation into myotubes, while mature IGF-1 and full-length IGF-1Eb produced the expected proliferative response in the same cells (Fornaro 2014). A critical review published before that had already noted that the case for a unique, independently acting MGF peptide rested on a small number of studies and that the proposed receptor had not been identified (Matheny 2010).

Where positive E-domain data do exist, it is mostly not muscle. In a gerbil model of transient brain ischaemia, the synthetic MGF C-terminal peptide gave significant protection to vulnerable neurons, and endogenous MGF expression rose in ischaemia-resistant hippocampal neurons (Dluzniewska 2005). In cardiac work, the E-domain peptide entered H9c2 cells without IGF-1 receptor activation, localised to the nucleus, blocked the intrinsic apoptotic pathway, and preserved cardiac function in mice after myocardial infarction (Mavrommatis 2013). Sheep given the MGF E domain after microsphere-induced infarction had better cardiac function and about 35% less compromised myocardium (Carpenter 2008).

So the E-domain probably does something. Whether it does the muscle thing it is sold for is exactly what failed to reproduce.

What the evidence shows

Human data

None interventional. There is no human trial of MGF peptide. The human data are descriptive: expression of the splice variant in biopsies after resistance exercise, with the young-versus-elderly difference described above (Hameed 2003), and cell work on primary human myoblasts, where the two main studies disagree (Kandalla 2011 versus Fornaro 2014).

The current review of GH-axis peptides places MGF and its pegylated form in the tier with no human studies, and notes that the mechanistic literature cited in support of “MGF-like” regenerative effects is largely about IGF-1Ec biology and synthetic E-domain constructs rather than about a characterised drug (Dominikowski 2026).

Animal and cell data, labelled as such

What is in the vials

Anti-doping laboratories have characterised a biotechnologically produced full-length MGF relevant to doping control (Thevis 2014), and separately identified an MGF variant, MGF R23H, in confiscated vials alongside BPC-157, with in vitro metabolism work showing it is stable enough to be detectable in urine (Cox 2017). Two points follow: products sold as MGF are not necessarily the 24-amino-acid E-domain peptide, and some circulating material is a modified variant.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

No human trial of MGF exists, so there is no trial dose to report. Every row below is practice or anecdote, and the honest framing is that these numbers came from forums rather than from pharmacology.

The timing argument, examined. MGF’s circulating half-life of a few minutes is why protocols insist on injecting immediately post-exercise into the trained muscle. That logic is internally consistent, and it is also the strongest single argument that an injection cannot do much: a peptide cleared in minutes has very little time to accomplish anything, and the body already produces this signal in response to the training session itself (Hameed 2003).

Titration. There is nothing to titrate against. No dose-response data exist in any species for the synthetic peptide, so the 100 to 400 mcg range is convention rather than calibration.

Technique and reconstitution are in the peptide injection guide.

What people report: what works and what doesn’t

Sources: the aggregated community data set (Peptide Protocol Wiki, 40 reports), a second protocol compilation (Peptide DB), and the patterns catalogued in the peer-reviewed review (Dominikowski 2026). Patterns, not proof. MGF has one of the smallest report bases of any peptide in this batch, which matters: fewer reports means a weaker signal either way.

Reported to work

• A local pump or fullness in the injected muscle for a few hours. Plausibly a volume and irritation effect rather than growth.
• Subjectively faster recovery when stacked with BPC-157 or TB-500, with the attribution to MGF itself impossible to separate.

Mixed or unclear

• Whether MGF does anything at all. This is unusual: the community itself is split, with the short half-life and the subcutaneous-versus-intramuscular question openly debated rather than settled.
• Site-specific growth. The rationale is stronger here than for IGF-1 LR3, since the natural molecule acts locally and clears in minutes, but no study has tested exogenous MGF injected into a specific muscle.
• MGF versus PEG-MGF. Convenience favours the pegylated form, locality favours the native one, and neither has human data.

Reported not to work, or disappointing

• Measurable muscle gain. The common conclusion is that MGF is not worth the injection burden, which lines up with the failed reproduction study.
• Adding MGF on top of an existing GH or IGF-1 protocol. Frequently described as indistinguishable from the protocol without it.
• Side effects: mostly injection-site soreness and lumps from repeated intramuscular dosing. Serious adverse effects are not described, which is unsurprising for a peptide cleared in minutes, and also not evidence of safety at scale.

What a properly designed trial would need to show: first, independent replication of a biological effect of the synthetic 24-amino-acid peptide on human muscle cells, given that the best-powered attempt was negative. Only then is a human study of post-exercise injection with muscle biopsy, satellite cell counts and strength endpoints worth running.

Safety and side effects

What is known. Essentially nothing systematic. There are no human safety data, no pharmacokinetic study in people, and no immunogenicity assessment. FDA states that for the pegylated form it identified no human exposure data for any route and lists possible immunogenicity risk for certain routes; the non-pegylated form sits in category 3 of the 503A list, which is a statement about inadequate supporting information rather than about safety.

Theoretical concerns worth naming.

• Proliferative signalling. Even though the E-domain appears not to act through IGF-1R, anything promising satellite cell proliferation deserves caution in people with a cancer history. There is no study of malignancy risk.
• Identity risk. Confiscated material has contained a variant, MGF R23H, rather than the native sequence (Cox 2017), and biotechnologically produced full-length MGF circulates as well (Thevis 2014). A vial labelled MGF may be any of these.
• Repeated intramuscular injection into the same muscle groups carries the ordinary risks of fibrosis, infection and abscess, and these are real-world problems in this population.

Interactions. Unstudied. The common combination with exogenous GH or IGF-1 analogues adds the metabolic risks of those compounds, including hypoglycaemia from IGF-1 analogues.

See peptide safety and peptide sourcing.

Legal and regulatory status

United States. No approved product. Mechano growth factor (MGF) appears in category 3 of FDA’s 503A bulk drug substance list (updated 14 May 2026), substances nominated without adequate supporting information, which means the interim enforcement policy for category 1 substances does not apply. The pegylated form appears on FDA’s separate table of substances previously in category 2 whose nominations were withdrawn, where FDA records possible immunogenicity risk for certain routes and that it identified no human exposure data. See the FDA 2026 compounding update.

European Union and Germany. No authorisation. Germany’s Anti-Doping Act (AntiDopG) annex lists “Mechano Growth Factor (MGF) und MGF-Varianten” among growth factors. Under § 2(3), acquiring, possessing or importing more than a “non-small quantity” for the purpose of doping in sport is an offence, and the quantity regulation (DmMV, in force 16 March 2023) sets that threshold at 3 mg for MGF and its variants.

Sport. Prohibited at all times under the WADA list, in the section covering peptide hormones, growth factors, related substances and mimetics, where mechano growth factors are named explicitly. Detection methods exist for full-length MGF and for the R23H variant (Thevis 2014, Cox 2017). See peptides and anti-doping rules.

How MGF fits

The last row of that table is the real argument. The one intervention proven to raise MGF expression in human muscle is a hard set of resistance exercise, and the main finding of interest in the field is that this response is blunted in older muscle (Hameed 2003). That is a question worth pursuing with proper research, and it is not the same thing as a reason to inject a peptide whose activity failed to reproduce.

For people whose real goal is muscle preservation or growth, peptides for muscle growth and sarcopenia prevention cover the interventions with actual human evidence behind them.

Related Articles

• PEG-MGF: PEGylation Without Human Data — the long-acting version and FDA’s position on it.
• IGF-1 LR3: Strong Pharmacology, Zero Human Trials — the systemic IGF-1 analogue people alternate with MGF.
• Peptides for Muscle Growth: What the Evidence Actually Supports — the honest hierarchy.
• Sarcopenia Prevention: Preserving Muscle Mass After 40 — what works for age-related muscle loss.
• Peptide Sourcing: Pharmaceutical-Grade vs. Grey Market — why vial identity is a live issue here.